Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare Biotechnology

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)

Bullboard Posts

Post by Amigo11on Jun 10, 2020 7:03am

298 Views

Post# 31132055

Valuation

With the help of nephew,the company ,via warrants,existing cash and cash from the raise,has about $45 mill in cash (another $5 mill if Citagenix is jettisoned).Able to bargain with strength-and thats about 10-12 cents of cash per share(assuming 430 mill shares fully diluted ).So for 30 cents a share or $130 mill you get the drug pipeline as it sits.I think the raise was necessary although poorly timed.Couldn't have done this raise 12 weeks ago in the middle of Covid and no certainty you can 12 weeks from now.The silver lining with a bought deal is that Antibe has strength.

Bullboard Posts

The top 5 Canadian small-cap AI stocks